A Proton Pump Inhibitor's Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study
Gut and Liver
; : 607-614, 2015.
Article
in En
| WPRIM
| ID: wpr-216110
Responsible library:
WPRO
ABSTRACT
BACKGROUND/AIMS:
Proton pump inhibitors (PPIs) act by irreversibly binding to the H+-K+-ATPase of the proton pump in parietal cells and may possibly affect the vacuolar H+-ATPase in osteoclasts.METHODS:
We investigated the effect of 8 weeks of PPI treatment on the parameters of bone turnover and compared PPI with revaprazan, which acts by reversibly binding to H+-K+-ATPase in proton pumps. This study was a parallel randomized controlled trial. For 8 weeks, either a PPI or revaprazan was randomly assigned to patients with gastric ulcers. The parameters of bone turnover were measured at the beginning of and after the 8-week treatment period.RESULTS:
Twenty-six patients (PPI, n=13; revaprazan, n=13) completed the intention-to-treat analysis. After the 8-week treatment period, serum calcium and urine deoxypyridinoline (DPD) were increased in the PPI group (serum calcium, p=0.046; urine DPD, p=0.046) but not in the revaprazan group. According to multivariate linear regression analysis, age > or =60 years was an independent predictor for the changes in serum calcium and urine DPD.CONCLUSIONS:
In elderly patients, administering a PPI for 8 weeks altered bone parameters. Our study suggested that PPIs might directly alter bone metabolism via the vacuolar H+-ATPase in osteoclasts.Key words
Full text:
1
Database:
WPRIM
Main subject:
Osteoclasts
/
Pyrimidinones
/
Bone and Bones
/
Linear Models
/
Calcium
/
Multivariate Analysis
/
Prospective Studies
/
Bone Remodeling
/
Tetrahydroisoquinolines
/
Proton Pump Inhibitors
Type of study:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
Limits:
Aged
/
Female
/
Humans
/
Male
Language:
En
Journal:
Gut and Liver
Year:
2015
Document type:
Article